TCM
AKBA icon

Tekla Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Tekla Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-213,942
Closed -$1.75M – 198
2019
Q1 		$1.75M Hold
213,942
– – 0.07% 137
2018
Q4 		$1.18M Sell
213,942
-52,670
-20% -$412K 0.05% 155
2018
Q3 		$2.35M Hold
266,612
– – 0.09% 144
2018
Q2 		$2.66M Buy
266,612
+133,763
+101% +$1.34M 0.1% 125
2018
Q1 		$1.27M Buy
+132,849
New +$1.86M 0.05% 153

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tekla Capital Management's AKBA Position: Q2 2019 in Review

Tekla Capital Management sold out of Akebia Therapeutics (AKBA) in Q2 2019, closing a stake of 213,942 shares — an estimated $1.75M sold.

Tekla Capital Management first reported a position in AKBA in Q1 2018 and held it in 5 quarters. The position peaked at $2.66M in Q2 2018. 151 funds tracked by Wall St. Rank hold AKBA as of Q2 2019.

  • Tekla Capital Management reported no remaining Akebia Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Tekla Capital Management sold 213,942 Akebia Therapeutics shares in Q2 2019, an estimated $1.75M.
  • Tekla Capital Management first reported a position in Akebia Therapeutics in Q1 2018 and held it in 5 quarters.
  • Tekla Capital Management's Akebia Therapeutics position peaked at $2.66M in Q2 2018.
  • 151 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2019.

Based on Tekla Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.